Veracyte, Inc.
VCYT
株式のランク
#4357
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
株価
$44.93
最終同期: 2026-10-20
時価総額
$3.61B
変化（1日）
2.57%
変化（1年）
24.45%
国
US
取引 Veracyte, Inc. (VCYT)
カテゴリー
Healthcare
Veracyte, Inc.（VCYT）の発行済株式数
June 2026 時点の発行済株式数 79.76M
Veracyte, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 79.76M です。December 2023 の終わりには、同社は 72.64M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Veracyte, Inc.（VCYT）の発行済株式数の履歴（2011 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 79.76M | 4.28% |
| 2024 | 76.48M | 5.29% |
| 2023 | 72.64M | 1.53% |
| 2022 | 71.55M | 5.39% |
| 2021 | 67.89M | 27.52% |
| 2020 | 53.24M | 15.39% |
| 2019 | 46.14M | 24.63% |
| 2018 | 37.02M | 9.12% |
| 2017 | 33.93M | 17.67% |
| 2016 | 28.83M | 11.12% |
| 2015 | 25.94M | 19.89% |
| 2014 | 21.64M | 420.34% |
| 2013 | 4.16M | -70.70% |
| 2012 | 14.20M | 0.00% |
| 2011 | 14.20M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 371.00M | 365.17% |
US
|
|
| 705.30M | 784.33% |
US
|
|
| 143.28M | 79.65% |
US
|
|
| - | - |
CN
|
|
| 282.00M | 253.58% |
US
|
